Everything below concerns GABA-A modulation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Catechins are polyphenols that are a major component of green tea extract. Green tea has been associated with decreasing blood glucose, inhibiting hepatic and body fat accumulation, and stimulating thermogenesis due to the catechins present in formulations. Moreover, catechins in the brain play a major role in satiety. Independent of the caffeine content, green tea has also been shown to increase energy expenditure and fat oxidation in humans. While green tea intake alone may not significantly reduce weight or BMI, combining intake with other strategies aimed at weight loss could be helpful for both loss and weight maintenance. Adjunctive Lifestyle Therapies: Emerging evidence suggests that integrating medical weight loss treatments with structured lifestyle interventions—such as personalized nutrition, physical activity plans, and psychological support—enhances long-term outcomes. Studies indicate that combining pharmacotherapy with behavioral counseling can lead to significantly greater weight reduction and maintenance compared to medication alone Adjunctive Lifestyle Therapies: Emerging evidence suggests that integrating medical weight loss treatments with structured lifestyle interventions—such as personalized nutrition, physical activity plans, and psychological support—enhances long-term outcomes. Studies indicate that combining pharmacotherapy with behavioral counseling can lead to significantly greater weight reduction and maintenance compared to medication alone.
== Aerobic == The aerobic enzyme has a structure homologous to the complex alpha/beta topology found in the gene product of human sulfatase-modifying factor 1 (SUMF1). Aerobic FGE converts a cysteine residue in the highly conserved consensus sequence CXPXR to fGly. To do so, FGE "activates" its target by utilizing mononuclear copper. The substrate first binds to copper, increasing reactivity of the substrate-copper complex with oxygen. Activation is then accomplished through oxidation of a cysteine residue in the substrate-copper complex. Due to the nature of this reaction, FGE is termed a "copper-dependent metalloenzyme.
The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted. 11 May – Scotland's warmest day of the year so far is recorded by the Met Office, with a temperature of 25.7 °C at Cassley. 13 May – At the High Court in Kilmarnock, Uber driver Kunathilinghan Mohanthas is sentenced to seven years in prison for killing Christopher Hanton, who he left for dead in Glasgow city centre after ordering him out of his car and knocking him over as he performed a three-point turn in August 2023. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland. 15 May – The Scottish Government declares a national housing emergency during a parliamentary debate at Holyrood, citing UK government budget cuts and austerity as the reasons for a shortage in housing. Justice Secretary Angela Constance confirms that the Scottish Government are to seek powers to facilitate the early release of prisoners in order to prevent overcrowding in prisons. The rules would only apply to those serving under four years and would not apply to those convicted of sexual or domestic violence related offences. 18 May – Four police officers are injured and 19 arrests made in Glasgow city centre as fans celebrate after Celtic win the Premiership.
Sources: en.wikipedia.org
=== Role of eRF3 === There have been many hypotheses on the function of eRF3 in the termination complex. An early hypothesis was that eRF3 helped eRF1 bind to the stop codon since eRF3 was structurally similar to EF-TU, which is a GTPase that brings charged tRNA molecules to the aminoacyl site of the ribosome in prokaryotic cells. Other hypothesis focus on the effects of GTP hydrolysis, which is mediated by eRF3, on eRF1. The pre-hydrolyzed GTP configuration of the termination complex favors eRF1 binding to the stop codon and orientating eRF1 to the peptide tRNA. The post-hydrolyzed GDP configuration promotes the release of the complex and dissociation of the ribosome. Additional studies hypothesis that the hydrolysis of GTP due to eRF3 allows the catalytic site of eRF1 to enter the p-site of the ribosome thus promoting the release of the nascent polypeptide.
==== Including Your Party prior to formation ==== In 2025, Jeremy Corbyn and Zarah Sultana founded a new political party, called Your Party. Prior to the announcement of these plans, polling was carried out about the idea for a hypothetical new party. After the announcement of the plan for a new party, more polling was carried out.
=== Colloidal suspensions === Without sufficient attraction forces (e.g., Van der Waals force) to aggregate the solid particles together and to remove them from solution by gravity (settling), they remain in suspension and form colloids. Sedimentation can be accelerated by high speed centrifugation. The compact mass thus obtained is sometimes referred to as a 'pellet'.
A central campaign theme for Trump's second presidential bid was "retribution". Trump framed the 2024 election as "the final battle", and openly promised to leverage the power of the presidency for political reprisals. Trump heavily ran on immigration as a central campaign focus. Trump's campaign focused on dark and apocalyptic rhetoric about the state of the country and predicting doom if he did not win. The Associated Press stated that "Trump's rallies take on the symbols, rhetoric and agenda of Christian nationalism." During his 2024 presidential campaign, Trump made numerous false and misleading statements. Trump has been described as using the "big lie" and firehose of falsehood propaganda techniques.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.